Influence of Bruton's Tyrosine Kinase (BTK) on Epithelial-Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC).
BTK
CSC
EMT
HNSCC
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
received:
31
07
2023
revised:
21
08
2023
accepted:
21
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Constitutively active kinases play a crucial role in carcinogenesis, and their inhibition is a common target for molecular tumor therapy. We recently discovered the expression of two oncogenic isoforms of Bruton's Tyrosine Kinase (BTK) in head and neck squamous cell carcinoma (HNSCC), Btk-p80 and BTK-p65. However, the precise role of BTK in HNSCC remains unclear. Analyses of a tissue microarray containing benign and malignant as well as inflammatory tissue samples of the head and neck region revealed the preferential expression of BTK-p80 in malignant tissue, whereas BTK-p65 expression was confirmed in over 80% of analyzed metastatic head and neck tumor cases. Therefore, processes associated with metastasis, like cancer stem cell (CSC) enrichment and the epithelial-mesenchymal transition (EMT), which in turn depend on an appropriate cytokine milieu, were analyzed. Treatment of HNSCC-derived cell lines cultured under 3D conditions with the BTK inhibitor AVL-292 caused reduced sphere formation, which was accompanied by reduced numbers of ALDH1A1
Identifiants
pubmed: 37685940
pii: ijms241713133
doi: 10.3390/ijms241713133
pmc: PMC10487612
pii:
doi:
Substances chimiques
Agammaglobulinaemia Tyrosine Kinase
EC 2.7.10.2
Cytokines
0
NF-kappa B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncotarget. 2016 Oct 25;7(43):69961-69975
pubmed: 27564106
J Exp Clin Cancer Res. 2019 Jun 14;38(1):260
pubmed: 31200752
Cell Stem Cell. 2023 Jun 1;30(6):818-831.e6
pubmed: 37267916
Front Cell Dev Biol. 2021 Apr 14;9:650414
pubmed: 33937249
Nat Rev Immunol. 2022 Mar;22(3):158-172
pubmed: 34155388
Cancer Res. 2010 Dec 1;70(23):9969-78
pubmed: 21098716
Mol Cancer Ther. 2010 Nov;9(11):2879-92
pubmed: 21062915
Mol Cancer. 2018 Feb 19;17(1):57
pubmed: 29455639
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):296-306
pubmed: 27750041
Mol Cancer Res. 2011 Dec;9(12):1658-67
pubmed: 21976712
MedComm (2020). 2021 Dec 16;2(4):618-653
pubmed: 34977871
Oncotarget. 2015 May 30;6(15):13255-68
pubmed: 26036311
Cancer Biol Ther. 2015;16(11):1604-15
pubmed: 26383180
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Mediators Inflamm. 2021 Jun 14;2021:9918379
pubmed: 34220337
Cancer Immunol Res. 2019 Nov;7(11):1760-1774
pubmed: 31624067
J Exp Clin Cancer Res. 2017 Jul 17;36(1):96
pubmed: 28716053
Am J Transl Res. 2016 Jul 15;8(7):3003-12
pubmed: 27508020
Med Oncol. 2022 Apr 29;39(5):60
pubmed: 35484352
Cell Oncol (Dordr). 2020 Dec;43(6):1067-1084
pubmed: 32705581
Cancer Invest. 2014 Nov;32(9):470-95
pubmed: 25254602
Onco Targets Ther. 2016 Apr 26;9:2447-53
pubmed: 27217768
Mol Oncol. 2022 Jan;16(2):347-367
pubmed: 34382739
Anticancer Res. 2020 Nov;40(11):6093-6099
pubmed: 33109547
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncogene. 2016 Aug 18;35(33):4368-78
pubmed: 26804170
Mol Carcinog. 1999 Oct;26(2):119-29
pubmed: 10506755
Curr Opin Immunol. 1994 Aug;6(4):623-30
pubmed: 7946052
Cancers (Basel). 2023 Jan 03;15(1):
pubmed: 36612306
Oncol Lett. 2020 Jan;19(1):965-971
pubmed: 31897209
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Semin Cancer Biol. 2018 Dec;53:139-155
pubmed: 30081228
Cell Death Dis. 2014 Sep 04;5:e1409
pubmed: 25188519
Cells. 2021 Jan 08;10(1):
pubmed: 33429846
J Cell Physiol. 2020 Jan;235(1):65-73
pubmed: 31206697
Blood. 2011 Jan 27;117(4):1329-39
pubmed: 21063022
Cell Physiol Biochem. 2018;47(2):567-578
pubmed: 29794474
Head Neck. 2007 Oct;29(10):959-71
pubmed: 17405170
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Cancer Res. 2004 Sep 15;64(18):6511-23
pubmed: 15374962
Gut. 2023 Jul 4;:
pubmed: 37402563
Front Oncol. 2019 Nov 08;9:1100
pubmed: 31788442
Front Immunol. 2017 Nov 08;8:1454
pubmed: 29167667
Oncogene. 2007 Feb 1;26(5):711-24
pubmed: 16862183
Leukemia. 2021 Feb;35(2):312-332
pubmed: 33122850
J Exp Med. 2000 May 15;191(10):1745-54
pubmed: 10811867
Head Neck. 2023 May;45(5):1162-1171
pubmed: 36939297
Oncogenesis. 2021 Feb 27;10(2):20
pubmed: 33640903
Cancers (Basel). 2020 Oct 07;12(10):
pubmed: 33036368
FEBS J. 2011 Jun;278(12):1990-2000
pubmed: 21362140
Crit Rev Immunol. 2009;29(4):317-33
pubmed: 19673686
Genes Chromosomes Cancer. 2013 Oct;52(10):961-75
pubmed: 23913792
J Cancer. 2019 Oct 21;10(26):6511-6525
pubmed: 31777581